Xeris Biopharma Holdings Inc (XERS)
3.095
+0.06
(+1.81%)
USD |
NASDAQ |
Nov 22, 13:22
Xeris Biopharma Holdings Enterprise Value: 615.09M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 615.09M |
| November 20, 2024 | 618.07M |
| November 19, 2024 | 610.62M |
| November 18, 2024 | 594.22M |
| November 15, 2024 | 597.20M |
| November 14, 2024 | 616.58M |
| November 13, 2024 | 631.49M |
| November 12, 2024 | 631.49M |
| November 11, 2024 | 650.87M |
| November 08, 2024 | 679.19M |
| November 07, 2024 | 662.80M |
| November 06, 2024 | 659.81M |
| November 05, 2024 | 647.89M |
| November 04, 2024 | 641.92M |
| November 01, 2024 | 643.42M |
| October 31, 2024 | 641.92M |
| October 30, 2024 | 643.16M |
| October 29, 2024 | 643.16M |
| October 28, 2024 | 643.16M |
| October 25, 2024 | 638.69M |
| October 24, 2024 | 644.65M |
| October 23, 2024 | 625.28M |
| October 22, 2024 | 611.87M |
| October 21, 2024 | 613.36M |
| October 18, 2024 | 617.83M |
| Date | Value |
|---|---|
| October 17, 2024 | 614.85M |
| October 16, 2024 | 614.85M |
| October 15, 2024 | 611.87M |
| October 14, 2024 | 604.42M |
| October 11, 2024 | 595.48M |
| October 10, 2024 | 576.11M |
| October 09, 2024 | 580.58M |
| October 08, 2024 | 599.95M |
| October 07, 2024 | 598.46M |
| October 04, 2024 | 605.91M |
| October 03, 2024 | 605.91M |
| October 02, 2024 | 595.48M |
| October 01, 2024 | 577.60M |
| September 30, 2024 | 586.54M |
| September 27, 2024 | 580.54M |
| September 26, 2024 | 574.58M |
| September 25, 2024 | 570.11M |
| September 24, 2024 | 573.09M |
| September 23, 2024 | 564.15M |
| September 20, 2024 | 589.48M |
| September 19, 2024 | 593.95M |
| September 18, 2024 | 585.01M |
| September 17, 2024 | 585.01M |
| September 16, 2024 | 582.03M |
| September 13, 2024 | 582.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
20.14M
Minimum
Apr 02 2020
679.19M
Maximum
Nov 08 2024
298.02M
Average
258.91M
Median
Sep 18 2020
Enterprise Value Benchmarks
| Zevra Therapeutics Inc | 456.85M |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
| Theriva Biologics Inc | -12.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.74M |
| Revenue (Quarterly) | 54.27M |
| Total Expenses (Quarterly) | 67.16M |
| EPS Diluted (Quarterly) | -0.11 |
| Gross Profit Margin (Quarterly) | 74.95% |
| Profit Margin (Quarterly) | -29.00% |
| Earnings Yield | -14.22% |
| Normalized Earnings Yield | -15.50 |